Lilly East

Safety, tolerability, and pharmacokinetics of casimersen in patients with <scp>D</scp>uchenne muscular dystrophy amenable to exon <scp>45</scp> skipping: A randomized, double‐blind, placebo‐controlled, dose‐titration trial

Kathryn R. Wagner, Nancy L. Kuntz, E. Koenig et al. · Muscle & Nerve · 2021 · 151 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +14

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

Pedro Cahn, Richard Kaplan, Paul E. Sax et al. · The Lancet HIV · 2017 · 35 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir

Rajesh Krishna, Lilly East, Patrick Larson et al. · Journal of Pharmacy and Pharmacology · 2016 · 25 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen

Drew MacCannell, Zdenek Berger, Lilly East et al. · Neuromuscular Disorders · 2021 · 23 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6–48 months with Duchenne muscular dystrophy amenable to exon 51 skipping

Eugenio Mercuri, A. Seferian, Laurent Servais et al. · Neuromuscular Disorders · 2023 · 23 citations · Full text

Pharmacy, Pediatrics, Pharmacokinetics +9